NEVVI Medicare utilization intelligence

← back

PATEL, PRASHANTMD NPI 1336135102 Clinician

Hematology-Oncology · STUART, FL

Specialty Hematology-Oncology — from billed Medicare claims
In practice about 43 years since medical school (class of 1983, self-reported to CMS)
Location STUART, FL · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 50 codes billed · 108,163 disclosed volume (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
STUART ONCOLOGY ASSOCIATES PA
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2009-11

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Volume Beneficiary-episodes Avg charge Avg Medicare payment
J1439 Injection, ferric carboxymaltose, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
36415 Insertion of needle into vein for collection of blood sample
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
80053 Blood test, comprehensive group of blood chemicals
96372 Injection of drug or substance under skin or into muscle
J7050 Infusion, normal saline solution, 250 cc
82746 Folic acid level, serum
82607 Cyanocobalamin (vitamin b-12) level
82728 Ferritin (blood protein) level
96413 Administration of chemotherapy into vein, 1 hour or less
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96360 Infusion into a vein for hydration, 31-60 minutes
83540 Iron level
J1200 Injection, diphenhydramine hcl, up to 50 mg
83550 Iron binding capacity
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96417 Administration of additional new drug or substance into vein, 1 hour or less
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
82378 Carcinoembryonic antigen (cea) protein level
99441 Telephone medical discussion with physician, 5-10 minutes
96415 Administration of chemotherapy into vein, each additional hour
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
84153 Psa (prostate specific antigen) measurement, total
84443 Blood test, thyroid stimulating hormone (tsh)
83615 Lactate dehydrogenase (enzyme) level
83735 Magnesium level
96375 Injection of additional new drug or substance into vein
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
84100 Phosphate level
81000 Manual urinalysis test with examination using microscope, non-automated
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
82270 Stool analysis for blood to screen for colon tumors
99212 Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
71260 Ct scan of chest with contrast
74177 Ct scan of abdomen and pelvis with contrast
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.